Evidence map›Paper›PMID 37345485›Full record

ArticleHaematologica2023

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia.

Julia S Lee, Charlotte B Wagner, Stacy Prelewicz, Heena P Kurish, Robert Walchack, Danielle A Cenin, Seema Patel, Mimi Lo, Danielle Schlafer, Belinda K T Li and 4 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Julia S LeeDepartment of Pharmacy, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT. julialee@stanfordhealthcare.org.
Charlotte B WagnerDepartment of Pharmacy, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.
Stacy PrelewiczDepartment of Pharmacy, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.
Heena P KurishDepartment of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH.
Robert WalchackDepartment of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH.
Danielle A CeninDepartment of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH.
Seema PatelDepartment of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH.
Mimi LoDepartment of Pharmaceutical Services, University of California San Francisco, San Francisco, CA.
Danielle SchlaferDepartment of Hematology and Medical Oncology, Winship Cancer Institute/Emory Healthcare, Atlanta, GA.
Belinda K T LiDepartment of Hematology and Medical Oncology, Winship Cancer Institute/Emory Healthcare, Atlanta, GA.
R Donald Harvey IiiDepartment of Hematology and Medical Oncology, Winship Cancer Institute/Emory Healthcare, Atlanta, GA.
Bestis WasefDepartment of Pharmacy, Oregon Health and Science University Hospital, Portland, OR.
Jian YingDivision of Public Health, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.
Tibor KovacsovicsDivision of Hematology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.
Cleveland Clinic · USEmory Healthcare · USHuntsman Cancer Institute · USUniversity of Utah · USOregon Health and Science University Hospital · USUniversity of California, San Francisco · US

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
NCATS NIH HHS UL1 TR002538
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

IdarubicinLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsCytarabinefms-Like Tyrosine Kinase 3HumansMutationRemission InductionStaurosporineCytarabineFLT3 protein, humanfms-Like Tyrosine Kinase 3IdarubicinmidostaurinStaurosporine

Identifiers

PMID37345485
PMCPMC10690909
OpenAlexW4381598589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.